The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.